News Eiger BioPharmaceuticals

Stocks

EIGR

US28249U2042

Biotechnology & Medical Research

Market Closed - OTC Markets 11:27:07 2024-09-27 EDT			5-day change	1st Jan Change
8.500 ^USD	-.--%		-.--%	-

24-10-01	Eiger BioPharmaceuticals Files for Chapter 11 Bankruptcy as Liquidation Plan Takes Effect	CI
24-09-30	Eiger BioPharmaceuticals, Inc. Went Out of Business	CI

All News

Mentions Relevance

24-10-01	Eiger BioPharmaceuticals Files for Chapter 11 Bankruptcy as Liquidation Plan Takes Effect	CI
24-10-01	Eiger BioPharmaceuticals : DEBTOR AFFILIATES PURSUANT TO CHAPTER 11 OF THE BANKRUPTCY CODE Form 8 K	PU
24-09-30	Eiger BioPharmaceuticals, Inc. Went Out of Business	CI
24-09-05	Combined Hearing for Disclosure Statement and Plan Approved for Eiger BioPharmaceuticals, Inc.	CI
24-09-05	Fifth Amended Joint Liquidation Plan Filed by Eiger BioPharmaceuticals, Inc.	CI
24-09-04	First Motion for Exclusivity Period Extension Approved For Eiger BioPharmaceuticals, Inc.	CI
24-09-03	Fourth Amended Joint Liquidation Plan Filed by Eiger BioPharmaceuticals, Inc.	CI
24-09-02	Eiger InnoTherapeutics, Inc. acquired Peginterferon Lambda Assets from Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $1 million.	CI
24-09-02	Eiger InnoTherapeutics, Inc. acquired Peginterferon Lambda Assets from Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $1 million.	CI
24-09-02	Eiger InnoTherapeutics, Inc. completed the acquisition of Lonafarnib Antiviral Asset of Eiger BioPharmaceuticals, Inc. from Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $5.2 million.	CI
24-08-28	Third Amended Joint Liquidation Plan & Disclosure Statement Filed by Eiger BioPharmaceuticals, Inc.	CI
24-08-21	Motion for Asset Sale Approved for Eiger BioPharmaceuticals, Inc.	CI
24-08-15	Second Amended Joint Liquidation Plan & Disclosure Statement Filed by Eiger BioPharmaceuticals, Inc.	CI
24-08-05	Motion for Asset Sale Filed by Eiger BioPharmaceuticals, Inc.	CI
24-08-02	Motion for Asset Sale Filed by Eiger BioPharmaceuticals, Inc.	CI
24-08-01	Eiger InnoTherapeutics, Inc. agreed to acquire Lonafarnib Antiviral Asset of Eiger BioPharmaceuticals, Inc. from Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $5.2 million.	CI
24-07-31	Eiger InnoTherapeutics, Inc. entered into Peginterferon Lambda Asset Purchase Agreement to acquire Peginterferon Lambda Assets from Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $1 million.	CI
24-07-31	Eiger InnoTherapeutics, Inc. entered into Peginterferon Lambda Asset Purchase Agreement to acquire Peginterferon Lambda Assets from Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $1 million.	CI
24-07-30	Disclosure Statement Conditionally Approved for Eiger BioPharmaceuticals, Inc.	CI
24-07-28	First Amended Joint Liquidation Plan & Disclosure Statement Filed by Eiger BioPharmaceuticals, Inc.	CI
24-07-23	First Motion for Exclusivity Period Extension Filed by Eiger BioPharmaceuticals, Inc.	CI
24-07-16	Eiger BioPharmaceuticals : THIS IS NOT A SOLICITATION OF ACCEPTANCE OR REJECTION OF THE PLAN. THE DEBTORS ARE SEEKING APPROVAL OF THE DISCLOSURE STATEMENT ON A CONDITIONAL BASIS, BUT IT HAS NOT YET BEEN APPROVED BY THE BANKRUPTCY COURT Form 8 K	PU
24-07-15	Jont Liquidation Plan and Disclosure Statement Filed by Eiger BioPharmaceuticals, Inc.	CI
24-07-01	Moshe Arkin Engages with Eiger BioPharmaceuticals	CI
24-06-26	Motion for Asset Sale Approved for Eiger BioPharmaceuticals, Inc.	CI